Published in final edited form as:

Bioorg Med Chem Lett. 2007 July 15; 17(14): 3872–3876. doi:10.1016/j.bmcl.2007.05.004.

Antiproliferative and Apoptosis Inducing Properties of Pyrano[3,2-*c*]pyridones Accessible by a One-Step Multicomponent Synthesis

Igor V. Magedov^{a,b,*}, Madhuri Manpadi^c, Nikolai M. Evdokimov^a, Eerik M. Elias^c, Elena Rozhkova^a, Marcia A. Ogasawara^c, Jennifer D. Bettale^d, Nikolai M. Przheval'skii^a, Snezna Rogelj^d, and Alexander Kornienko^{c,*}

^aDepartment of Organic Chemistry, Timiryazev Agriculture Academy, Moscow 127550, Russia

^bIntelbioscan Ltd., Timiryazevsky Proesd 2, Moscow 127550, Russia

^cDepartment of Chemistry, New Mexico Institute of Mining and Technology, Socorro, New Mexico 87801, USA

^dDepartment of Biology, New Mexico Institute of Mining and Technology, Socorro, New Mexico 87801, USA

Abstract

4-Arylpyrano-[3,2-*c*]-pyridones have been prepared by a one-step cyclocondensation of 4-hydroxy-1,6-dimethylpyridin-2(1*H*)-one with various substituted benzaldehydes and malononitrile. These heterocycles exhibit micromolar and submicromolar antiproliferative activity in HeLa and induce apoptosis in Jurkat cell lines. Structure-activity studies performed on a small library of these compounds show a pronounced cytotoxicity enhancing effect of the bromo substituent at the meta position of the C4 aromatic moiety.

Keywords

Multicomponent synthesis; Cytotoxicity; Apoptosis; Heterocycles

2-Pyridone structural unit occurs in many natural and synthetic molecules exhibiting diverse biological activities.¹ A few selected examples include antitumor antibiotic diazaquinomycin A,² a non-nucleoside HIV reverse transcriptase inhibitor L-697,661³ and a phosphodiesterase inhibitor milrinone,⁴ used in the clinic for the treatment of heart failure (Figure 1).

Many libraries of compounds containing a 2-pyridone moiety fused with another heterocyclic ring have been prepared and tested for various biological activities. Somewhat surprisingly, the biology of 4*H*-pyrano-[3,2-*c*]-pyridin-5(6*H*)-ones (**A**, Figure 2) has not been thoroughly investigated with the exception of antibacterial properties associated with some of these compounds.⁵ For example, a literature search reveals that pyranopyridones **B**,

© 2007 Elsevier Ltd. All rights reserved.

*Corresponding authors. Tel.: +1 505 835 5884; fax: +1 505 835 5364; intelbioscan@mtu-net.ru, akornien@nmt.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

whose preparation by way of cyclocondensation of arylidene malononitriles with 4-hydroxypyridine-2-ones has been reported on many occasions,⁶ have not been evaluated for biological activities. In contrast, a number of recent publications and patents have described promising anticancer activity, associated with chromenes **C**.⁷ These compounds, shown to inhibit tubulin polymerization and induce apoptosis in cancer cells, exhibit high potency against taxol- and vinblastine-resistant, P-glycoprotein overexpressing cell types.^{7d} Furthermore, chromenes **C** disrupt tumor vasculature in a number of human solid tumor xenografts and they are currently in development as anticancer agents.^{7b,c}

Extensive SAR studies performed with chromenes **C** show that substituents on the benzene ring at positions 7 and 8 (R^7 and R^8) are well tolerated, while the introduction of substituents at positions 5 and 6 (R^5 and R^6) results in inactive compounds. Furthermore, replacement of the benzene ring of the chromene scaffold with a heterocyclic moiety has not been reported to the best of our knowledge. We reasoned that pyridones **B** would represent an interesting test because of the partial aromatic character of this ring brought about by the amide resonance conjugation. In addition, the amide group would be placed into the part of the structure that is most sensitive to alterations. Finally, amide resonance conjugation would make the compounds more polar addressing water solubility issues of the parent chromenes **C**.⁸

The synthesis of the pyridones **B** library is shown in Figure 3. Pyridone **1** was prepared by treating the corresponding commercially available pyrone with aqueous MeNH_2 following a literature procedure.⁹ A three-component reaction of pyridone **1** with malononitrile and various aromatic aldehydes in a 1:1:1 ratio proceeds smoothly in refluxing ethanol containing a small quantity of Et_3N .¹⁰ Pyranopyridones **2–12** precipitate directly from the refluxing reaction mixtures and require no further purification. The product yields are given in Table 1.^{11,12}

The analogue library was tested for antiproliferative activity using HeLa cell line as a model for human cervical adenocarcinoma. The cells were treated with respective compounds for 48 h and cell viability was assessed through measurements of mitochondrial dehydrogenase activity using MTT method (Table 1).¹³ It is noteworthy that all potent analogues have a 3-bromo substituent on the aromatic ring at position C4 of the pyranopyridone skeleton (compounds **2–8**) and this preference is uniform irrespective of the substitution pattern of this aromatic moiety. The 3-chloro (**9**) and other variously substituted analogues (**10–12**) are significantly less potent or are totally inactive. Further, the substitution of the nitrogen in the pyridone ring by oxygen, as in pyranopyranone **13**, abolishes the activity as well. Moderate potency of the N-(β -arylethyl)pyridone **14**, synthesized in a manner analogous to the rest of the library, warrants further investigation of compounds having a bulky moiety on the pyridone nitrogen. Efforts to prepare a library of such compounds are underway in our laboratories.

Since many clinically used anticancer agents induce apoptosis in cancer cells, we tested the pyranopyridone analogues for their ability to induce apoptosis in Jurkat cells using a flow cytometric annexin-V/propidium iodide assay (Figure 4). Compounds **2–8**, exhibiting submicromolar or low micromolar potencies for the inhibition of proliferation of HeLa cells, were found to be strong inducers of apoptosis in Jurkats at 5 μM concentrations. The magnitude of apoptosis induction (50–60 % after 36 h treatment) is comparable to the known antimitotic agent colchicine used at the same concentration. In contrast, compounds **9**, **11**, **14**, which are much less potent or totally inactive in the HeLa MTT assay, show no apoptosis induction of Jurkats at this concentration.

For comparison we selected some of the most potent chromene **C** (Figure 2) analogues on the basis of the literature data (e.g. R⁵, R⁶, R⁸ = H; R⁷ = NMe₂; X = 3,4,5-*tri*-OMe or X = 3-Br-4,5-*di*-OMe),⁷ synthesized and evaluated them in our assays. While the chromenes are significantly more cytotoxic to HeLa cells (IC₅₀ = 1–10 nM), the magnitude of apoptosis induction in Jurkats is similar to compounds **2–8** (50–55% at 5 μM).

The images of Jurkat cells after 48 h treatment are shown in Figure 5. Cells treated with an inactive compound **11** (Figure 5B) look similar to the DMSO treated counterparts (Figure 5A). In contrast, extensive deformation and fragmentation are observed with cells treated with a potent analogue **3** (Figure 5C).

Lastly, the flow cytometric cell cycle analysis, performed with pyranopyridones **2** and **3** using Jurkat cell line, shows pronounced cell cycle arrest in the G₂/M phase (Table 2). This effect is characteristic of antimetabolic agents disrupting microtubule assembly, and is also observed with chromenes **C** that bind to or near the colchicine binding site on β-tubulin.^{7d} This observation is indicative of the antitubulin mechanism for pyranopyridones **B** similar to the one established for chromenes **C**.

Further optimization of the pyranopyridone library with the aim of identifying more potent analogues as well as more detailed mechanistic studies are underway and will be reported in due course.

Acknowledgments

Russian Foundation for Basic Research (grant 07-03-00577 to I.V.M) and US National Institutes of Health (grants CA-99957 and RR-16480 to A.K. and S.R) are gratefully acknowledged for financial support of this work. We thank Professors Scott T. Shors and Patrick S. Mariano for helpful suggestions.

References and notes

1. See Gorobets, NYu; Yousefi, BH.; Belaj, F.; Kappe, CO. *Tetrahedron*. 2004; 60:8633. and references cited therein.
2. Pettit GR, Du J, Pettit RK, Richert LA, Hogan F, Mukku JVRV, Hoard MS. *J Nat Prod*. 2006; 69:804. [PubMed: 16724845]
3. Saag MS, Emini EA, Laskin OL, Douglas J, Lapidus WI, Schleif WA, Whitley RJ, Hildebrand C, Byrnes VW, Kappes JC, Anderson KW, Massari FE, Shaw GM. *N Engl J Med*. 1993; 329:1065. [PubMed: 7690462]
4. Hasegawa GR. *Clin Pharmacy*. 1986; 5:201.
5. (a) Choudhari BP, Mulwad VV. *Indian J Chem Sect B-Org Chem Incl Med Chem*. 2003; 42:2080. (b) Balasubramanian C, Sekar M, Mohan PS. *Indian J Chem Sect B-Org Chem Incl Med Chem*. 1996; 35:1225.
6. (a) Elagamey AGAE, Sawellim SZ, El-Taweel FMA, Elnagdi MH. *Coll Czech Chem Commun*. 1988; 53:1534. (b) El-Taweel FMA, Sofan MA, Mashaly MA, Hanna MA, Elagamey AA. *Pharmazie*. 1990; 45:671. (c) Sowellim SZA, El-Taweel FMAA, Elagamey AGA. *Bull Soc Chim Fr*. 1996; 133:229. (d) El-Nabi HAA. *Pharmazie*. 1997; 52:28. (e) Mekheimer RA, Mohamed NH, Sadek KU. *Bull Chem Soc Jpn*. 1997; 70:1625. (f) Dodia N, Shah A. *Indian J Heterocycl Chem*. 2000; 10:155. (g) Stoyanov EV, Ivanov IC, Heber D. *Molecules*. 2000; 5:19. (h) Dodia N, Shah A. *Heterocycl Commun*. 2001; 7:289. (i) Stadlbauer W, Badawey ES, Hojas G, Roschger P, Kappe T. *Molecules*. 2001; 6:338. (j) Mulwad VV, Lohar MV. *Indian J Heterocycl Chem*. 2002; 12:57. (k) Rodinovskaya LA, Shestopalov AM, Gromova AV. *Russ Chem Bull, Int Ed*. 2003; 52:2185. (l) Rodinovskaya LA, Shestopalov AM, Shestopalov AA, Litvinov VP. *Russ Chem Bull, Int Ed*. 2005; 54:992. (m) El-Taweel FMAA. *J Heterocyclic Chem*. 2005; 42:943. (n) Rodinovskaya LA, Shestopalov AM, Gromova AV, Shestopalov AA. *Synthesis*. 2006:2357.
7. (a) Kemnitzer W, Kasibhatla S, Jiang S, Zhang H, Zhao J, Jia S, Xu L, Crogan-Grundy C, Denis R, Barriault N, Vaillancourt L, Charron S, Dodd J, Attardo G, Labrecque D, Lamothe S, Gourdeau H,

- Tseng B, Drewe J, Cai SX. *Bioorg Med Chem Lett*. 2005; 15:4745. [PubMed: 16143530] (b) Gourdeau H, Leblond L, Hamelin B, Desputeau C, Dong K, Kianicka I, Custeau D, Boudreau C, Geerts L, Cai S-X, Drewe J, Labrecque D, Kasibhatla S, Tseng B. *Mol Cancer Ther*. 2004; 3:1375. [PubMed: 15542776] (c) Kasibhatla S, Gourdeau H, Meerovitch K, Drewe J, Reddy S, Qiu L, Zhang H, Bergeron F, Bouffard D, Yang Q, Herich J, Lamothe S, Cai SX, Tseng B. *Mol Cancer Ther*. 2004; 3:1365. [PubMed: 15542775] (d) Kemnitzer W, Drewe J, Jiang S, Zhang H, Wang Y, Zhao J, Jia S, Herich J, Labreque D, Storer R, Meerovitch K, Bouffard D, Rej R, Denis R, Blais C, Lamothe S, Attardo G, Gourdeau H, Tseng B, Kasibhatla S, Cai SX. *J Med Chem*. 2004; 47:6299. [PubMed: 15566300] (e) Cai, SX.; Jiang, S.; Kemnitzer, WE.; Zhang, H.; Attardo, G.; Denis, R.; Storer, R.; Rej, R. PCT Int Appl WO 2003097806. 20031127. 2004. p. A2(f) Cai, SX.; Jiang, S.; Attardo, G.; Denis, R.; Storer, R.; Rej, R. PCT Int Appl WO 2003096982. 20031127. 2003. p. A2(g) Cai, SX.; Zhang, H.; Jiang, S.; Storer, R. PCT Int Appl WO 2002092594. 20021121. 2002. p. A1(h) Cai, SX.; Xu, L.; Storer, R.; Attardo, G. PCT Int Appl WO 2002092083. 20021121. 2002. p. A1(i) Cai, SX.; Zhang, H.; Kemnitzer, WE.; Jiang, S.; Drewe, JA.; Storer, R. PCT Int Appl WO 2002092076. 20021121. 2002. p. A1(j) Drewe, JA.; Cai, SX.; Wang, Y. PCT Int Appl WO 2001034591. 20010517. 2001. p. A2
8. The calculated log P values are 1.5–2 units lower for pyranopyridones **B** (log P ~ 2–2.5) compared with the previously reported (Ref. 7d) 7-Me₂N-substituted (R⁵, R⁶, R⁸ = H; R⁷ = NMe₂) chromenes **C** (log P ~ 3.5–4.5).
 9. Castillo S, Ouadahi H, Herault V. *Bull Soc Chim Fr*. 1982:257.
 10. To our knowledge this is the first example of a multicomponent reaction used for the preparation of pyrano-[3,2-c]-pyridones. However, such process has been described for the synthesis of the corresponding quinolones utilizing KF-Al₂O₃ as a catalyst: Wang XS, Zeng ZS, Shi DQ, Wei XY, Zong ZM. *Synth Commun*. 2004; 34:3021.
 11. *General procedure for the synthesis pyrano-[3,2-c]-pyridones 2–12*: A mixture of 4-hydroxy-1,6-dimethylpyridin-2(1*H*)-one (0.8 mmol), malononitrile (0.8 mmol), triethylamine (0.05 mL) and a corresponding aldehyde (0.8 mmol) in EtOH (96% aqueous solution, 3 mL) was refluxed for 50 minutes. The reaction mixture was allowed to cool to room temperature, the precipitated product was collected by filtration and washed with EtOH (5 mL). In all cases the product was > 98% pure as judged by ¹H NMR analysis.
 12. *Selected Characterization Data*: Compound **2**: 83%; mp 248–250 °C (EtOH); ¹H NMR (DMSO-d₆) δ 7.27–7.08 (m, 5H), 6.06 (s, 1H), 4.28 (s, 1H), 3.33 (s, 3H), 2.66 (s, 6H), 2.33 (s, 3H); ¹³C NMR (DMSO-d₆) δ 161.7, 159.8, 155.4, 153.7, 148.8, 145.0, 143.1, 122.9, 112.7, 105.5, 97.4, 60.5, 56.6, 39.3, 37.2, 31.2, 20.8; HRMS *m/z* (ESI) calcd for C₁₉H₁₉BrN₄O₂ (M+Na⁺) 437.0589, found 437.0580. Compound **4**: 88%; mp 258–260 °C (EtOH); ¹H NMR (DMSO-d₆) δ 7.09 (s, 2H), 6.90 (s, 1H), 6.79 (s, 1H), 6.07 (d, *J* = 2.7 Hz, 1H), 4.33 (d, *J* = 3.0 Hz, 1H), 3.92 (q, *J* = 3.0 Hz, 2H), 3.76 (s, 3H), 3.33 (s, 3H), 2.33 (s, 3H), 1.27 (t, *J* = 3.0 Hz, 3H); ¹³C NMR (DMSO-d₆) δ 161.6, 159.8, 155.4, 153.8, 148.6, 144.3, 142.7, 122.9, 117.5, 112.6, 105.5, 97.42, 68.9, 57.8, 56.6, 37.1, 31.1, 20.8, 16.1; HRMS *m/z* (ESI) calcd for C₂₀H₂₀BrN₃O₄ (M+Na⁺) 468.0535, found 468.0540. Compound **5**: 75%; mp 246–247 °C (EtOH); ¹H NMR (DMSO-d₆) δ 9.32 (s, 1H), 7.04 (s, 2H), 6.82–6.71 (m, 2H), 6.06 (s, 1H), 4.28 (s, 1H), 3.77 (s, 3H), 3.32 (s, 3H), 2.34 (s, 3H); ¹³C NMR (DMSO-d₆) δ 161.6, 159.6, 155.1, 148.5, 148.4, 143.0, 137.5, 123.1, 111.5, 109.6, 105.9, 97.4, 58.0, 56.7, 37.0, 31.1, 20.8; HRMS *m/z* (ESI) calcd for C₁₈H₁₆BrN₃O₄ (M+Na⁺) 440.0222, found 440.0223.
 13. Mosmann T. *J Immunol Methods*. 1983; 65:55. [PubMed: 6606682]

diazaquinomycin A

L - 697,661

milrinone

Figure 1.
Structures of biologically active 2-pyridone-containing compounds.

Figure 2.
Structures of the scaffold **A**, pyranopyridone library **B** and chromene library **C**.

Figure 3.
Three-component synthesis of pyrano-[3,2-*c*]-pyridones.

Figure 4. Induction of apoptosis in Jurkat cells treated for 36 h with DMSO control, colchicine (5 μ M) and selected pyridone library analogues (5 μ M) in flow cytometric annexin-V/propidium iodide assay. Error bars represent data from two experiments.

Figure 5. Jurkat cells after 48 h treatment with DMSO control (A), inactive compound **11** (B) and potent analogue **3** (C).

Table 1

Synthetic yields and antiproliferative activity of pyrano-[3,2-*c*]-pyridones.

Analogue	Ar	Synthesis	Compound concentration required to reduce HeLa cell viability by 50 % after 48 h treatment relative to 100 % DMSO control as assessed with MTT assay in three independent experiments	IC ₅₀ (1), μ M	IC ₅₀ (2), μ M	IC ₅₀ (3), μ M	IC ₅₀ , μ M	SD, μ M
2			83	0.3	0.3	0.4	0.33	0.06
3			87	0.75	0.5	0.5	0.58	0.14
4			88	2	0.75	0.5	1.08	0.8
5			75	2	2	4	2.67	1.1

Analogue	Ar	Synthesis	Compound concentration required to reduce HeLa cell viability by 50 % after 48 h treatment relative to 100 % DMSO control as assessed with MTT assay in three independent experiments				
			% Yield	IC ₅₀ (1), μ M	IC ₅₀ (2), μ M	IC ₅₀ (3), μ M	SD, μ M
6			83	4	2	4.5	1.3
7			84	7	7	5	1.1
8			97	7.5	7	5	1.3
9			98	20	15	20	2.9
10			97	40	50	40	5.1

Analogue	Ar	Synthesis	Compound concentration required to reduce HeLa cell viability by 50 % after 48 h treatment relative to 100 % DMSO control as assessed with MTT assay in three independent experiments				
			% Yield	IC ₅₀ (1), μ M	IC ₅₀ (2), μ M	IC ₅₀ (3), μ M	SD, μ M
11			81	> 100	> 100	> 100	n/a
12			97	20	25	60	21.8
13			87	> 100	> 100	> 100	n/a

Analogue	Ar	Synthesis	Compound concentration required to reduce HeLa cell viability by 50 % after 48 h treatment relative to 100 % DMSO control as assessed with MTT assay in three independent experiments											
			% Yield	IC ₅₀ (1), μ M	IC ₅₀ (2), μ M	IC ₅₀ (3), μ M	IC ₅₀ , μ M	SD, μ M
80	30	18	20	22.7	6.4

14

6.4														

Table 2

Flow cytometric cell cycle analysis of Jurkat cells.

Compound	% Relative DNA content $\pm$ SD after 15 h treatment as assessed with Vybrant Orange staining		
	G ₀ /G ₁	S	G ₂ /M
DMSO	49.4 $\pm$ 2.7	26.6 $\pm$ 0.1	23.9 $\pm$ 2.4
2 (5 μ M)	14.4 $\pm$ 1.7	18.1 $\pm$ 0.6	67.5 $\pm$ 2.3
3 (5 μ M)	12.0 $\pm$ 3.5	19.0 $\pm$ 2.0	68.5 $\pm$ 4.7
colchicine (25 μ M)	19.0 $\pm$ 0.2	23.1 $\pm$ 0.1	57.9 $\pm$ 0.1